| Name | Title | Contact Details |
|---|
Campaign for Better Health Care is a Chicago, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
West Pharmaceutical Services, Inc. is a leading manufacturer of packaging components and delivery systems for injectable drugs and healthcare products. Working by the side of its customers from concept to patient, West creates products that promote the efficiency, reliability and safety of the world`s pharmaceutical drug supply. West is headquartered in Exton, Pennsylvania, and supports its customers from locations in North and South America, Europe, Asia and Australia. West`s 2019 sales of $1.84 billion reflect the daily use of more than 100 million of its components and devices, which are designed to improve the delivery of healthcare to patients around the world.
Day Kimball Hospital is a non-profit, 103 bed community hospital located in Putnam, Connecticut.
NeuWave Medical specializes in developing and commercializing energy-based minimally invasive medical devices. These devices must deliver improved healthcare economics and a better experience for patients in terms of outcomes or quality of life. NeuWave Medical, Inc. is a spin-off company from the University of Wisconsin - Madison. NeuWave arose as the result of an academic collaboration between engineers and physicians who wished to improve their ability to treat cancer and other important clinical problems. As a result, NeuWave is highly focused on solving real clinical problems in a manner that will directly benefit patients by being more effective, minimally invasive, and cost conscious.
Nivalis Therapeutics (formerly N30Pharma) is developing a novel class of disease modifying therapies that preserve intracellular GSNO (S-nitrosoglutathione), a key regulator of organ repair, regeneration, and healing. The Company’s lead program is focused on cystic fibrosis. As the body’s primary reservoir of nitric oxide (NO), GSNO plays a pivotal role in NO signaling. Decreased GSNO levels are associated with inflammatory lung disease, and with increased activity of GSNOR (GSNO reductase), the primary catabolizing enzyme of GSNO. Nivalis Therapeutics has developed a broad portfolio of proprietary, potent, small molecule inhibitors of GSNOR that have been shown to preserve endogenous GSNO levels and to be effective in “gold-standard” models of inflammatory lung disease. Nivalis Therapeutics is located in Boulder, Colorado.